当前位置:首页>产品中心>单抗/多抗>Anti-Human PLIN5 Polyclonal Antibody|抗人PLIN5多克隆抗体(靶标:人脂滴包被蛋白5)

Anti-Human PLIN5 Polyclonal Antibody|抗人PLIN5多克隆抗体(靶标:人脂滴包被蛋白5)

  • 货号:RB9THC071014
  • 价格:面议
  • 点击:311

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Human
靶标LSDP5, Lipid storage droplet protein 5, OXPAT, PAT-1, PLIN5, Perilipin-5
免疫原E. coli - derived recombinant Human PLIN5 (Asn21-Val369).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q00G26
背景信息

Perilipin-5 (PLIN5) is a ~50 kDa protein. Lipid droplet-associated protein that maintains the balance between lipogenesis and lipolysis and also regulates fatty acid oxidation in oxidative tissues. Recruits mitochondria to the surface of lipid droplets and is involved in lipid droplet homeostasis by regulating both the storage of fatty acids in the form of triglycerides and the release of fatty acids for mitochondrial fatty acid oxidation. In lipid droplet triacylglycerol hydrolysis, plays a role as a scaffolding protein for three major key lipolytic players: ABHD5, PNPLA2 and LIPE. Reduces the triacylglycerol hydrolase activity of PNPLA2 by recruiting and sequestering PNPLA2 to lipid droplets. Phosphorylation by PKA enables lipolysis probably by promoting release of ABHD5 from the perilipin scaffold and by facilitating interaction of ABHD5 with PNPLA2.

备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 532
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 334
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 530
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 286
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 391
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 536
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 498
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 596
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 458
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 239
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 403
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 297
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 551
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 458
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 433
Anti-Elotuzumab Non-Neutralizing Recombinant Antibody|抗埃罗妥珠单抗非中和重组抗体(靶标:埃罗妥珠单抗非中和抗体) 573
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 234
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 318
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 290
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 290
总计 33037 个记录,共 1652 页,当前第 1649 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00